These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20801905)

  • 1. ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy.
    Besse B; Massard C; Haddad V; Andre F; Dunant A; Pirker R; Olaussen KA; Brambilla E; Fouret P; Soria JC
    Ann Oncol; 2011 Mar; 22(3):575-581. PubMed ID: 20801905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
    Olaussen KA; Dunant A; Fouret P; Brambilla E; André F; Haddad V; Taranchon E; Filipits M; Pirker R; Popper HH; Stahel R; Sabatier L; Pignon JP; Tursz T; Le Chevalier T; Soria JC;
    N Engl J Med; 2006 Sep; 355(10):983-91. PubMed ID: 16957145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
    Pierceall WE; Olaussen KA; Rousseau V; Brambilla E; Sprott KM; Andre F; Pignon JP; Le Chevalier T; Pirker R; Jiang C; Filipits M; Chen Y; Kutok JL; Weaver DT; Ward BE; Soria JC
    Ann Oncol; 2012 Sep; 23(9):2245-2252. PubMed ID: 22269178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome.
    Cubukcu E; Fatih Olmez O; Saraydaroglu O; Akcali U; Kanat O; Kurt E; Evrensel T; Manavoglu O
    Clin Transl Oncol; 2011 Nov; 13(11):826-30. PubMed ID: 22082649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
    Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.
    Wislez M; Barlesi F; Besse B; Mazières J; Merle P; Cadranel J; Audigier-Valette C; Moro-Sibilot D; Gautier-Felizot L; Goupil F; Renault A; Quoix E; Souquet PJ; Madroszyck A; Corre R; Pérol D; Morin F; Zalcman G; Soria JC
    J Clin Oncol; 2014 Apr; 32(12):1256-61. PubMed ID: 24638013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].
    Hirai Y; Yoshimasu T; Oura S; Tamaki T; Ota F; Nakamura R; Shimizu Y; Naito K; Ota M; Miyasaka M; Okamura Y; Nakamura Y; Yasuoka H; Kodama R
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):611-4. PubMed ID: 19381033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ERCC1 and lung cancer].
    Planchard D; Olaussen KA; Soria JC
    Rev Mal Respir; 2010 Apr; 27(4):387-94. PubMed ID: 20403548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA; Mountzios G; Soria JC
    Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
    De Dosso S; Zanellato E; Nucifora M; Boldorini R; Sonzogni A; Biffi R; Fazio N; Bucci E; Beretta O; Crippa S; Saletti P; Frattini M
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):159-65. PubMed ID: 23645290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
    Friboulet L; Olaussen KA; Pignon JP; Shepherd FA; Tsao MS; Graziano S; Kratzke R; Douillard JY; Seymour L; Pirker R; Filipits M; André F; Solary E; Ponsonnailles F; Robin A; Stoclin A; Dorvault N; Commo F; Adam J; Vanhecke E; Saulnier P; Thomale J; Le Chevalier T; Dunant A; Rousseau V; Le Teuff G; Brambilla E; Soria JC
    N Engl J Med; 2013 Mar; 368(12):1101-10. PubMed ID: 23514287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
    Fujii T; Toyooka S; Ichimura K; Fujiwara Y; Hotta K; Soh J; Suehisa H; Kobayashi N; Aoe M; Yoshino T; Kiura K; Date H
    Lung Cancer; 2008 Mar; 59(3):377-84. PubMed ID: 17905465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
    Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
    Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
    J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    Mol Biol Rep; 2012 Jun; 39(6):6933-42. PubMed ID: 22302397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.